Extended recombinant polypeptides and compositions comprising same

A method of treating a disease, disorder or condition, comprising administering a therapeutically effective dose of a pharmaceutical composition to a subject in need thereof,

• wherein the pharmaceutical composition comprises a fusion protein and one or more pharmaceutically acceptable excipients,
• wherein the fusion protein comprises an extended recombinant polypeptide linked to a biologically active protein (BP),
• wherein the extended recombinant polypeptide comprises an amino acid sequence which has at least 90% sequence identity to SEQ ID NOs:
• 205, 208, 211, 461-465, 467-477, 479, 480-485, 487-489, 491-504, 699, 772, or 793,
• wherein the extended recombinant polypeptide comprises a motif of SEQ ID NO:
• 190, SEQ ID NO:
• 192, or SEQ ID NO:
• 193,
• wherein the disease, disorder or condition is type 1 diabetes, type 2 diabetes, obesity, hyperglycemia, hyperinsulinemia, decreased insulin production, insulin resistance, syndrome X, excessive appetite, insufficient satiety, glucagonomas, dyslipidemia, retinal neurodegenerative processes, Factor VII deficiency, Factor X deficiency, Factor XII deficiency, hemophilia A, hemophilia B, Von Willebrand's disease, hypertension, acute coronary syndrome, rheumatoid arthritis, reperfusion injury following ischemia, growth-hormone deficiency, Turner's Syndrome, Prader-Willi Syndrome, idiopathic short stature, AIDS wasting, multiple sclerosis, Crohn's disease, ulcerative colitis, muscular dystrophy, or surgical bleeding.